September 25, 2023 News by Patricia Inacio, PhD Data: Lucid-MS seen to be safe, well tolerated in healthy volunteers FSD Pharmaās Lucid-21-302 ā an oral treatment candidate known as Lucid-MS, for all types of multiple sclerosis (MS) ā was found safe and well tolerated across multiple doses in healthy volunteers, according to interim data from a Phase 1 clinical trial. The newly released data are from the…
May 15, 2023 News by Margarida Maia, PhD 1st group of healthy volunteers dosed in Phase 1 trial of ‘Lucid-MS’ FSD Pharma has completed dosing in the first group of healthy volunteers enrolled in its Phase 1 clinical trial testing Lucid-21-302, an oral medication candidate for all types of multiple sclerosis (MS). The medication, also known as Lucid-MS, was first given to a sentinel subject ā one…
April 20, 2023 News by Margarida Maia, PhD First participant completes dosing in Phase 1 Lucid-MS trial The first participant has completed dosing in a Phase 1 clinical trial testing FSD Pharma‘s Lucid-21-302, an experimental oral medication for all types of multiple sclerosis (MS), in healthy volunteers. After receiving a green light from Health Canada to launch the first-in-human trial, the company began by…
February 9, 2023 News by Andrea Lobo, PhD Health Canada clears Phase 1 trial of Lucid-MS in healthy volunteers FSD Pharma will soon launch a first-in-human trial testing Lucid-21-302, known as Lucid-MS ā its novel chemical treatment for multiple sclerosis (MS)Ā ā in healthy volunteers. Health Canada has cleared the company to initiate a Phase 1 clinical trial of the investigational therapy, FSD Pharma announced in a…
January 18, 2023 News by Marisa Wexler, MS FSD Asking to Open Trial of Lucid-MS, Myelin-protecting Therapy FSD Pharma has submitted an application to Health Canada asking to start a Phase 1 clinical trial of Lucid-MS, the company’s experimental and myelin-protective oral therapy for people withĀ multiple sclerosis (MS). The trial will not involve patients and is designed to investigate the safety and tolerability of…
December 6, 2021 News by Patricia Inacio, PhD Lucid-MS Restores Motor Function in Mouse Model, Company Says Lucid-MS, a new chemical molecule being developed by FSD Pharma for the treatment of multiple sclerosis (MS), has shown the ability to restore motor function in an animal model of the disease, the company announced. After about 50 days of treatment, animals receiving Lucid-MS showed a marked decrease…